R&D | March 10, 2026
UK pushes space-made medicines from orbit to patients with new support package
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The first of four planned modules at the new plant is expected to come online by summer 2026
Huwel’s diagnostic solutions leverage open RT-PCR system
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
